OncoMatch/Clinical Trials/NCT03999723
Combining Active and Passive DNA Hypomethylation
Is NCT03999723 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for myelodysplastic syndromes.
This is a multicentre, randomized, parallel-group, placebo-controlled, double-blind phase 2 study of the efficacy and safety of oral vitamin C supplement in combination with azacitidine in patients with higher-risk MDS, CMML-2 or low-blast count AML. The primary purpose is to investigate if oral vitamin C supplementation to azacitidine, compared with azacitidine + placebo, can increase the effectiveness of epigenetic therapy in patients with higher-risk myeloid malignancies, who are not candidates for allogeneic hematopoietic stem cell transplantation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: hypomethylating agent
Prior therapy with hypomethylating agents
Cannot have received: radiation therapy
Exception: therapy-related MDS eligible if no radiation or chemotherapy for six months
Therapeutic radiation or chemotherapy within the past 6 months
Cannot have received: chemotherapy
Exception: therapy-related MDS eligible if no radiation or chemotherapy for six months
Therapeutic radiation or chemotherapy within the past 6 months
Lab requirements
Liver function
total serum bilirubin ≤1.5 × uln, serum alanine transaminase ≤3 × uln, no chronic hepatitis with decompensated cirrhosis
Cardiac function
no severe cardiac disease (nyha class 3-4)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify